Press Releases Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
1,519 ^JPY	+1.67%		+2.64%	+6.90%

Apr. 18	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
Apr. 17	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	Apr. 17	AQ
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	Apr. 16	AQ
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	Apr. 14	AQ
Nxera Pharma joins the World Orphan Drug Alliance	Apr. 08	AQ
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC	Apr. 03	AQ
Nxera Pharma is the New Name for Sosei Group	Mar. 31	AQ
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma	Mar. 27	AQ
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease	Mar. 20	AQ
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	Mar. 20	AQ
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia	Mar. 11	AQ
Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals	Mar. 06	AQ
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office	Feb. 15	AQ
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023	Feb. 13	AQ
Sosei Heptares Webinar Presentation for FY2023 Financial Results	Jan. 22	AQ
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer	Jan. 05	AQ
Sosei : Shared Research, Inc. Issued an Analyst Report on Sosei Group Corporation	Dec. 26	PU
Sosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare Conference	Dec. 21	AQ
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea	Dec. 07	AQ
Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies	Dec. 06	AQ
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	Nov. 24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Press Releases

Filters